Browsing by Author "Heinrich, B."

Now showing items 1-4 of 4

    • Article  

      Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC-ECSG phase II clinical study 

      Gamucci, T.; Paridaens, R.; Heinrich, B.; Schellens, J. H. M.; Pavlidis, Nicholas; Verweij, J.; Sessa, Cristiana; Kaye, Stanley B.; Roelvink, M.; Wanders, J.; Hanauske, A. R. (2000)
      Background: GI147211 is a water-soluble synthetic analogue of camptothecin showing promising in vivo and in vitro antitumor activity and an acceptable toxicity profile. Patients and methods: Between April 1995 and November ...
    • Article  

      Multicentre phase II pharmacological evaluation of rhizoxin 

      McLeod, H. L.; Murray, L. S.; Wanders, J.; Setanoians, A.; Graham, M. A.; Pavlidis, Nicholas; Heinrich, B.; Huinink, W. W. Ten Bokkel; Wagener, D. J. Th; Aamdal, S.; Verweij, J. (1996)
      Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines and xenograft models. ...
    • Article  

      Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies 

      Schellens, J. H. M.; Heinrich, B.; Lehnert, M.; Gore, M. E.; Kaye, Stanley B.; Dombernowsky, P.; Paridaens, R.; Oosterom, A. T. Van; Verweij, J.; Loos, W. J.; Calvert, H.; Pavlidis, Nicholas; Cortes-Funes, H.; Wanders, J.; Roelvink, M.; Sessa, Cristiana; Selinger, K.; Wissel, P. S.; Gamucci, T.; Hanauske, A. R. (2002)
      Population pharmacokinetic-dynamic analysis was prospectively integrated in a broad phase II program of lurtotecan (GI147211), a novel camptothecin derived topoisomerase I inhibitor, to determine the population pharmacokinetic ...
    • Article  

      Single agent activity of rhizoxin in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group 

      Kaplan, S.; Hanauske, A. R.; Pavlidis, Nicholas; Bruntsch, U.; Velde, A. Te; Wanders, J.; Heinrich, B.; Verweij, J. (1996)
      In a multicentre trial of the EORTC-Early Clinical Trials Group (ECTG) we treated 31 chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) with rhizoxin, a novel tubulin-binding agent. The drug was ...